Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Intra-operative intravenous fluid restriction reduces perioperative red blood cell transfusion in elective cardiac surgery, especially in transfusion-prone patients: a prospective, randomized controlled trial

  • George Vretzakis1,
  • Athina Kleitsaki1,
  • Konstantinos Stamoulis1,
  • Metaxia Bareka1,
  • Stavroula Georgopoulou1,
  • Menelaos Karanikolas2Email author and
  • Athanasios Giannoukas3
Journal of Cardiothoracic Surgery20105:7

https://doi.org/10.1186/1749-8090-5-7

Received: 30 November 2009

Accepted: 24 February 2010

Published: 24 February 2010

Abstract

Background

Cardiac surgery is a major consumer of blood products, and hemodilution increases transfusion requirements during cardiac surgery under CPB. As intraoperative parenteral fluids contribute to hemodilution, we evaluated the hypothesis that intraoperative fluid restriction reduces packed red-cell (PRC) use, especially in transfusion-prone adults undergoing elective cardiac surgery.

Methods

192 patients were randomly assigned to restrictive (group A, 100 pts), or liberal (group B, 92 pts) intraoperative intravenous fluid administration. All operations were conducted by the same team (same surgeon and perfusionist). After anesthesia induction, intravenous fluids were turned off in Group A (fluid restriction) patients, who only received fluids if directed by protocol. In contrast, intravenous fluid administration was unrestricted in group B. Transfusion decisions were made by the attending anesthesiologist, based on identical transfusion guidelines for both groups.

Results

137 of 192 patients received 289 PRC units in total. Age, sex, weight, height, BMI, BSA, LVEF, CPB duration and surgery duration did not differ between groups. Fluid balance was less positive in Group A. Fewer group A patients (62/100) required transfusion compared to group B (75/92, p < 0.04). Group A patients received fewer PRC units (113) compared to group B (176; p < 0.0001). Intraoperatively, the number of transfused units and transfused patients was lower in group A (31 u in 19 pts vs. 111 u in 62 pts; p < 0.001). Transfusions in ICU did not differ significantly between groups. Transfused patients had higher age, lower weight, height, BSA and preoperative hematocrit, but no difference in BMI or discharge hematocrit. Group B (p < 0.005) and female gender (p < 0.001) were associated with higher transfusion probability. Logistic regression identified group and preoperative hematocrit as significant predictors of transfusion.

Conclusions

Our data suggest that fluid restriction reduces intraoperative PRC transfusions without significantly increasing postoperative transfusions in cardiac surgery; this effect is more pronounced in transfusion-prone patients.

Trial registration

NCT00600704, at the United States National Institutes of Health.

Background

Cardiac surgery is a major blood product consumer. Data from many studies suggest that blood transfusions are associated with increased morbidity and mortality in cardiac surgery [1, 2]. However, a recent large observational study did not show an association between moderate (≤6 units) blood product exposure and reduced long-term survival [3]. As the risk of transfusion-associated adverse outcomes may depend on the amount of transfusion [4], reduction of blood transfusions is considered a relevant, important goal in cardiac surgery.

During cardiac operations under CPB, two concurrent events, namely blood loss and red blood cell dilution due to positive fluid balance result in precipitous hematocrit drop and need for allogeneic blood. Hemodilution has been identified as a major factor influencing the decision to transfuse. Likewise, several variables associated with total red cell mass, such as preoperative anemia, female gender and small body size, are independent predictors of transfusion in cardiac surgery [58]. Existing guidelines underline the importance of limiting hemodilution, applying blood salvage techniques and using alternative therapies for transfusion and blood conservation [7].

Surprisingly, data on the impact of intraoperative parenteral fluid restriction on transfusion needs are very limited. Recently, we published a RCT involving 130 pts operated for CABG under CPB supported by reinfusion of washed shed blood from thoracic cavities, and reported significant reduction of intraoperative PRC transfusions with a restrictive parenteral fluid protocol [9]. However, as only a small proportion of cardiac surgery patients are "transfusion-prone" (as defined by low preoperative hematocrit, female sex, or small BSA) our earlier study did not have adequate power to evaluate the role of fluid restriction on patients prone to transfusion. In contrast, the present study included a higher number of patients, and had adequate power for investigating the impact of perioperative intravenous fluid restriction on red blood cell transfusions not only in cardiac surgery patients in general, but also in the subset of patients who are considered transfusion-prone.

Methods

Patient selection and anesthesia

This prospective study was conducted in our University Hospital over a 20-month period, after approval from the Institution Ethics committee, and written informed consent was obtained from all patients before entering the study.

Inclusion criteria were elective cardiac surgery under CPB and ages 18 - 85. Exclusion criteria were emergency or re-do operations, operations starting after 18.00, recent administration of TPA or other thrombolytic medications, pre-existing hematologic disease or coagulation abnormality, advanced cirrhosis, renal failure, preoperative blood product transfusion, combined cardiac and carotid surgery and operations with minimal extracorporeal flow (surgery of ascending aorta) or circulatory arrest.

All patients received standardized anesthesia and intraoperative care, and were operated by the same team (same surgeon, assistant and perfusionist) under standardized conditions (same operating room and setting) with CPB and intra-operative cell salvage. Acute normovolemic hemodilution and retrograde autologous priming of the CPB circuit were not used in any patient. Antiplatelet medications (except aspirin) were discontinued at least 72 hours before surgery. Pharmacologic agents used to decrease blood loss in cardiac surgery (such as aprotinin, aminocaproic acid or tranexamic acid) were not used in any patient.

Monitoring included 5-lead ECG, ST-segment analysis, mixed venous oximetry plus continuous cardiac output recording (Oximetry TD catheter, Edwards Lifesciences, Germany), bispectral index (BIS/XP, Aspect Medical Systems, USA) and near-infrared spectroscopy to asses cerebrovascular hemoglobin oxygen saturation (INVOS 5100, Somanetics, USA).

All patients received total intravenous anesthesia with propofol and remifentanil. Neuromuscular blockade was maintained with cis-atracurium. The CPB pump and tubing (Stockert SIII, Germany; circuit: Custom Pack, Dideco, Italy) were primed with 1400 - 2000 mls of crystalloid, based on patient somatometric characteristics. Anticoagulation was achieved with heparin 300 IU/kg of body weight and ACT > 400 s was required before initiating CPB. Pump flow was 2.3-2.5 liter/min/m2. All patients received antegrade cardioplegia. Isolated CABG patients were operated under mild passive hypothermia down to 33.5-34.0°C, while systemic drift to 32.0°C was applied on all other patients. The lowest bladder temperatures recorded during CPB were not different between groups (34.58 ± 0.66°C in group A vs. 34.55 ± 0.57°C in group B). Most CABG patients received one internal mammary artery graft plus saphenous veins grafts. Active rewarming to 37.5°C bladder temperature and proper cardiac reperfusion were applied on all patients. After weaning from CPB, protamine 3 mg/kg was given to neutralize heparin. Remaining CPB circuit blood together with blood saved from the operation field was washed, centrifuged (Electa, Dideco, Italy) and re-transfused. Red cell salvage continued until the operation finished. Postoperatively all patients were admitted to the ICU, and the same hypnotic-analgesic regimen continued. Criteria for weaning from mechanical ventilation included hemodynamic stability with minimal or no cathecholamine support, absence of significant dysrhythmias, absence of major bleeding, core body temperature > 36°C, proper level of consciousness and acceptable blood gases with good respiratory mechanics. Postoperative pain was controlled with intravenous morphine infusion. Patients transferred to the ward when their clinical condition and laboratory findings were acceptable.

Study protocol

Surgeon, assistants, perfusionist and ICU personnel were not informed about the study. Anesthesiologists knew there was an ongoing study, but were not informed about the scope and aims of the study. Perfusionists followed common guidelines for cell saver use. Patients meeting inclusion criteria were randomly (using computer-generated numbers) allocated to either group A (restrictive protocol) or group B (control, IV fluid administration "as usual", based on all available hemodynamic data).

The following protocol was applied in group A: Intravenous (IV) fluids before CPB were limited to 500 ml. Peripheral IV lines were connected to hydroxyethylstarch (Voluven, 6% HES 130/0.4, Fresenius Kabi, France) and were turned off after central line placement. However, IV fluids were given quickly (within 3-5 minutes) in 50 ml increments when necessary. Anesthetic and inotropic or vasoactive solutions were double-concentrated and administered proximally through the central venous line without a "carrier" fluid infusion. Blood aspirated for sampling was re-infused and excessive line flashing was avoided. Before CPB, hemodynamic instability was managed according to the following algorithm:
  1. A)

    for MAP < 55 mmHg with SvO2 > 75%, INVOS > 60% and BIS < 35 titration of anesthetic drugs [*]

     
  2. B)

    for MAP <55 mmHg with SvO2 > 75%, INVOS > 60% and BIS > 35 vasoconstrictor [*]

     
  3. C)

    for SvO2 < 75%, PCWP ≥ 16 mmHg and heart rate < 90 b/min dobutamine

     
  4. D)

    for SvO2 < 75% and heart rate < 40 b/min pacing via epicardial electrode

     

[*] regardless of filling pressures

After applying the above corrective measures, each anesthesiologist was free to re-evaluate the patient and act according to his/her judgment for any other scenario.

Patients allocated in group B, received Ringer's Lactate solution through their peripheral IV line; drugs were diluted as usual and administered together with a "carrier" infusion at 40 ml/h. Anesthesiologists did not have to follow any specific fluid administration protocol, except for intraoperative PRC transfusion. Access to BIS and INVOS data was unrestricted, and anesthesiologists were free to manage the patient based on their judgment. In both groups, peripheral tissue perfusion/oxygenation was evaluated throughout the procedure, using all available hemodynamic data, including mixed venous oxygen saturation.

Indications for perioperative PRC transfusion

Perioperative transfusion decisions were made by the attending anesthesiologist, based on the following hematocrit-based rules: During AOX, allogeneic blood was not given if hematocrit was >21%. For values less than 17%, one unit of PRC was transfused. When hematocrit was between 17-21%, anesthesiologists were free to act based on their judgment when treating group B patients. In contrast, when treating fluid-restricted (group A) patients, anesthesiologists were expected to take INVOS values into consideration when deciding about transfusions, as follows: If mean INVOS value from both hemispheres was less than 60 or had decreased by 20% or more, compared to mean value during pulmonary artery catheter insertion, the patient was transfused.

In both groups, after AOX removal and before weaning from CPB (usually near completion of the last proximal anastomosis or during cardiac reperfusion), PRCs were transfused for hematocrit less than 21%. After weaning from CPB and re-transfusion of salvaged blood, patients were transfused for hematocrit ≤24%. In the ICU, patients were transfused for hematocrit ≤24%, while transfusion decisions for hematocrit values between 24-30% were evaluated in a multimodal manner.

Data collection and statistical analysis

Power analysis for sample size estimation was based on the following assumptions: The total number of PRC units transfused during hospital stay is the main outcome. Mean value of PRC transfusions during hospital stay is 3 units, Standard Deviation is 2 units, and reducing transfusions by one PRC unit is a clinically meaningful improvement compared to standard practice. These assumptions are consistent with data from our institution and also with published data [10]. Based on these assumptions, the study requires 60 patients per group, when α is set at 0.05 and power (1-β) is set at 0.8. However, we decided to enroll up to 100 patients per group, to allow for patient attrition or missing data, and also in order to look for differences with regards to transfusion between patient subgroups.

Total IV fluid volume administered and urine produced before CPB, during CPB and from CPB termination to the end of surgery were recorded for each patient. Priming and cardioplegic solution volumes, additional fluid given during CPB, hemofiltration volumes and pump residual volumes were also recorded. Hematocrit values were recorded preoperatively, after arterial line placement, after anesthesia induction, 10 minutes after CPB started, before CPB termination, at the end of surgery, 6 and 12 hours after ICU admission and before discharge from the hospital. BMI and BSA were calculated with standard formulas. Based on body weight and gender, net erythrocyte volume loss from the day before surgery until hospital discharge, and erythrocyte volume of transfused PRC units were calculated for each patient for the entire hospitalization. Data were stored electronically in Excel and were analyzed with SPSS 15.0 for Windows (SPSS Inc, Chicago, IL).

Continuous data normality was tested with the Kolmogorov-Smirnov test (Lilliefors significant correction) and Shapiro-Wilk test. Demographic and clinical patient characteristics were compared between groups using chi-square test for categorical data and Student's two-tailed t-test for continuous data. "Transfusion" was treated as a dichotomous variable, dividing patients in two subgroups: those who did and those who did not receive PRC transfusions. The association between group assignment (fluid restriction vs. liberal fluids) and gender with transfusion was evaluated with Pearson chi-square and Fisher's exact tests. The association of age, weight, height, BMI, BSA, preoperative Hct and discharge Hct with transfusion were tested with parametric (independent samples T-test) and non parametric (Mann-Whitney U) analyses. P-values < 0.05 were considered significant for all tests. Finally, a logistic regression model was constructed, to evaluate the association of all the above variables with probability of PRC transfusion using the Nagelkerke R2 and Cox & Snell R2 tests.

Results

Prospectively 192 cardiac surgery patients were randomly assigned to group A (100 patients, restrictive IV fluid administration protocol) or group B (92 patients, liberal IV fluid administration). Baseline demographic and clinical characteristics did not differ significantly between groups (Table 1).
Table 1

Demographic, clinical and transfusion data by patient group

Variable

Group A (fluid restriction)

Group B (liberal fluid administration)

Number of pts, n

100

92

Age (years)

66.0 ± 7.9

65.5 ± 8.3

Female gender, n (%)

17 (17.0%)

16 (17.4%)

Weight (kg)

77.2 ± 11.5

75.5 ± 10.6

Height (cm)

167.0 ± 7.8

168.0 ± 7.7

BMI

27.6 ± 3.5

26.7 ± 3.1

BSA (m2)

1.84 ± 0.17

1.84 ± 0.16

NYHA I-II, n (%)

57 (57.0%)

55 (59.8%)

NYHA III-IV, n (%)

43 (43.0%)

37 (40.2%)

LVEF (%)

50.2 ± 10.2

48.6 ± 12.1

Diabetes , n (%)

21 (21.0%)

20 (21.7%)

COPD, n (%)

14 (14.0%)

12 (13.0%)

Preop. Hct (%)

40.2 ± 4.42

40.6 ± 3.87

CABG, n (%)

88 (88.0%)

79 (85.9%)

Number of grafts

2.8 ± 0.6

2.7 ± 0.6

AVR + CABG

4 (4%)

4 (4.3%)

AVR

5 (5%)

6 (6.5%)

MVR

3 (3%)

2 (2.1%)

ASD Repair

0 (0%)

1 (1.1%)

CPB time (min)

96.9 ± 22.6

93.1 ± 20.0

AOX (min)

69.2 ± 20.0

67.9 ± 19.2

Operation time (min)

243 ± 49.4

236 ± 47.1

PRC transfused (total)

113 (1.13 ± 1.15*)

176 (1.91 ± 1.35)

PRC transfused in OR, n (mean ± SD)

31 (0.31 ± 0.71*)

111 (1.21 ± 3.15)

PRC transfused in ICU, n (mean ± SD)

82 (0.82 ± 0.98*)

65 (0.71 ± 0.88)

Transfused pts, n (%)

62 (62.0%)

75 (81.5%)

Transfused pts in OR, n (%)

19 (19.0%)

62 (67.4%)

Transfused pts in ICU, n (%)

51 (51.0%)

42 (45.7%)

PRC/pt transfused in OR (mean ± SD)

1.63 ± 0.68 **

1.79 ± 0.70

PRC/pt transfused in ICU (mean ± SD)

1.61 ± 0.78 **

1.55 ± 0.63

Females transfused, n (%)

16 (94.1%)

16 (100.0%)

Pts receiving ≥ 4 PRC u (OR + ICU)

2 (2.0%)

13 (14.1%)

* denotes mean ± SD for the distribution of PRC units/pt in total

** denotes mean ± SD for the distribution of PRC units per transfused patient

p < 0.001

p < 0.0001

Transfusion data for the entire hospitalization are shown in Table 1. Overall, during hospital stay 137 patients were transfused, receiving 289 units of PRCs, and the total number of PRC units transfused was significantly lower in group A (113 units) compared to group B (176 units, p < 0.0001). The percentage of patients receiving PRC transfusions was significantly lower in group A (62 of 100 patients) compared to group B (75 of 92 patients, p < 0.001).

Intraoperatively, 81 patients were transfused, receiving 142 units of PRCs. The number of intraoperative PRC transfusions was significantly lower in group A (31 units) compared to group B (111 units, p < 0.0001), and the percentage of patients receiving intraoperative transfusions was significantly lower in group A (19 of 100 in group A, vs. 62 of 92 in group B, p < 0.0001).

In the ICU, 93 patients received a total of 147 PRC units, and the number of PRC transfusions was slightly, but not significantly higher in group A (82 units) compared to group B (65 units). Likewise, the percentage of patients receiving transfusions in the ICU was slightly higher in group A (51 of 100 in group A, vs. 42 of 92 in group B), but the difference was not significant.

Table 2 presents demographic and clinical OR and ICU data, after dividing study patients to those transfused and those not transfused. Transfused patients had significantly higher age, lower height, weight and BSA, and lower preoperative hematocrit compared to those not transfused, whereas BMI and discharge hematocrit did not differ significantly. Male gender and assignment to group A (restrictive protocol) were strongly (p < 0.003) associated with lower probability of transfusion (Table 3).
Table 2

Baseline demographic and clinical (OR and ICU) data on transfused (n = 137) and not transfused patients (n = 55).

 

Group Statistics

Independent samples tests

 

Transfusion

Levene's test

t-test for equality of means (equal variances assumed)

  

mean ± SD

Sig.

Sig (2-tailed)

Mean differ.

Std error differ.

96% CI* lower/upper

Age

NO

63.6 ± 9.8

0.007

0.016

-3.09

1.27

-5.59/0.58

 

YES

66.7 ± 7.1

     

Weight

NO

79.3 ± 11.2

0.563

0.020

4.09

1.75

0.64/7.55

 

YES

75.2 ± 10.9

     

Height

NO

171.0 ± 6.2

0.12

0.000

4.94

1.19

2.60/7.29

 

YES

166.1 ± 7.9

     

BMI

NO

27.1 ± 3.2

0.442

0.745

-0.17

0.53

-1.22/0.88

 

YES

27.2 ± 3.4

     

BSA

NO

1.90 ± 0.15

0.949

0.001

0.90

0.02

0.04/0.14

 

YES

1.81 ± 0.16

     

pre-op. Hct

NO

42.1 ± 3.78

0.81

0.000

2.42

0.64

1.16/3.69

 

YES

39.6 ± 4.10

     

discharge Hct

NO

32.8 ± 2.21

0.829

0.586

-1.19

0.35

-0.87/0.49

 

YES

33.0 ± 2.15

     

* Confidence interval of the difference

Table 3

Results of Chi-square tests evaluating the association of Transfusion with Fluid administration protocol and Gender.

  

Cross-tabs

Chi-square tests

  

Transfusion

Asympt. Sig. (2-sided)

Exact. Sig. (2-sided)

Exact. Sig. (1-sided)

 
  

NO

YES

    

Fluid admin

Restricted

38

62

0.003

  

Pearson chi square

 

Liberal

17

75

 

0.004

0.002

Fisher's exact test

Gender

Male

54

105

0.000

  

Pearson chi square

 

Female

1

32

 

0.000

0.000

Fisher's exact test

Table 4 presents data after dividing patients within each group, in two subgroups, based on whether they received intraoperative PRC transfusions or not. Among patients transfused in the OR, significant difference existed between patients belonging in group A and B for gender, age and BSA (Table 4). Logistic regression modelling (Tables 5 &6) identified three variables as significant predictors of transfusion: fluid administration policy (group assignment), preoperative hematocrit and BSA (Table 5). The model explains nearly 21.5% (Nagelkerke R2, Table 6) of the observed variability regarding receiving a transfusion or not, and shows that the likelihood of PRC transfusion is 3.12 times greater in group B compared to group A. Furthermore, each 1% increase of preoperative hematocrit is associated with 15% (CI 5% - 26%) lower probability of transfusion.
Table 4

Patient data, with each patient group divided in two subgroups, based on whether patients were transfused in the operating room or not

Variable

Group A (fluid restriction)

Group B (liberal fluid administration)

 

Transfused (19 pts)

Not transfused (81 pts)

Transfused (62 pts)

Not transfused (30 pts)

Age (yr)

70.4 ± 4.76

65.0 ± 8.15

65.5 ± 7.42 ##

63.4 ± 9.59

Females, n (%)

8 (47.0%)

9 (52.9%)

14 (87.5%)

2 (12.5%)

Weight (kg)

72.9 ± 12.12

78.2 ± 11.24

74.5 ± 9.30

77.4 ± 12.81

Height (cm)

160.3 ± 5.63

168.6 ± 7.38

166.5 ± 7.98

171.0 ± 6.40

BMI

28.4 ± 4.77

27.4 ± 3.17

26.8 ± 2.83

26.4 ± 3.59

BSA (m2)

1.73 ± 0.14

1.87 ± 0.17

1.81 ± 0.15 #

1.88 ± 0.17

Preop. Hct (%)

38.4 ± 2.86

40.6 ± 4.62

39.9 ± 3.77

41.9 ± 3.79

# p < 0.05, ## p < 0.01, p < 0.001, p < 0.0001, when comparing transfused Group A patients vs. Transfused Group B patients.

Table 5

Variables in the Logistic Regression Equation

        

95% CI for EXP(B)

  

B

S.E.

Wald

df

Sig.

Exp(B)

Lower

Upper

Step

Group (A)

-1.137

0.364

9.767

1

0.002

0.321

0.157

0.654

1a

Pre-op Hct

-0.139

0.046

9.107

1

0.003

0.87

0.795

0.952

 

BSA

-2.728

1.103

6.114

1

0.013

0.065

0.008

0.568

 

Constant

12.320

2.571

22.957

1

0.000

224214.3

  

a. Variable(s) entered on step 1: BSA

SE: Standard Error, df: degrees of freedom, CI: confidence interval

Table 6

Logistic Regression model summary

Step

-2 Log likelihood

Cox & Snell R Square

Nagelkerke R Square

1

198.839a

0.15

0.215

a Estimation terminated at iteration number 5

Results concerning the number of PRC units transfused per patient are displayed in Table 7 and graphically presented in Figure 1. Significantly more Group A patients received 0 or 1 PRC unit, whereas significantly more Group B patients received 3, 4 or more PRC units (p < 0.0007). Statistical analysis of the association between the two most significant parameters derived from logistic regression (group assignment and preoperative hematocrit) with the number of PRCu/pt could not reach any safe conclusions, but increased PRC u/pt negatively correlated to the number of patients receiving such transfusion in group A.
Figure 1

Number of transfused PRC units/patient. Significantly more Group A patients received 0 or 1 PRC unit, whereas significantly more Group B patients received 3, 4, or more PRC units (p < 0.0007).

Table 7

Cross-tabulation of transfused PRC units per patient (combined OR and ICU data) by group.

PRC units per patient

GROUP A

GROUP B

TOTAL

0

38

17

55

1

26

17

43

2

25

31

56

3

9

14

23

≥4

2

13

15

TOTAL

100

92

192

Significantly more Group A patients received 0 or 1 units, whereas more Group B patients received 3, 4, or more units (p < 0.0007).

Table 8 shows hematocrit values for the entire observation period. Hematocrit decreased in both groups 10 minutes after CPB initiation and gradually increased towards discharge, presenting insignificant difference between groups at that point. Hematocrit values differed significantly between groups in sampling 3 (p < 0.05) and 4 (p < 0.005), but did not differ at any time during ICU stay. Data on fluid balance are also displayed in table 8. Only 9 of 100 group A patients received more than 500 ml of IV fluids before CPB. For this period, hydroxyethylstarch represented 95% of volume administered in group A but only 50% in group B, with the rest being crystalloid (not including saline for drug dialyses). Fluid administered in the period before CPB differed significantly between groups (p < 0.0001). Likewise, between CPB initiation and the first cardioplegia administration (sampling 4), fluid balance differed significantly between groups (p < 0.0001). Urine output and fluid balance while on CPB [ = (pump prime + total cardioplegia + any other "extra" volume in the CPB machine) - (urine + hemofiltration volume + residual CPB circuit volume)] are also displayed. Urine output did not differ between groups. Fluid balance for the entire procedure was significantly lower in group A (390 ± 432) compared to group B (667 ± 553, p < 0.001). Calculated net erythrocyte volume loss during the entire procedure was significantly lower in group A (758 ± 299 ml) compared to group B (903 ± 303 ml, p < 0.005).
Table 8

Hematocrit values and fluid balance by patient group.

HEMATOCRIT VALUES

Group A

Group B

1. Preoperative

40.21 ± 4.42

40.57 ± 3.87

2. After arterial line placement

39.59 ± 4.72

39.04 ± 4.41

3. After anesthesia induction

37.81 ± 4.69

36.44 ± 4.03#

4. After first cardioplegia

21.26 ± 3.49

19.96 ± 3.56#

5. End of CPB

24.53 ± 3.06

24.10 ± 2.30

6. End of operation

27.23 ± 3.20

26.46 ± 2.29

7. 6 hours in the ICU

28.98 ± 3.37

28.34 ± 2.49

8. 12 hours in the ICU

30.30 ± 2.79

30.67 ± 2.60

9. Day of discharge

32.74 ± 2.22

33.13 ± 2.09

FLUID BALANCE

  

IV fluids (ml) to initiation of CPB

328 ± 157

642 ± 222

urine (ml) to initiation of CPB

141 ± 106

169 ± 111

fluid balance after 1st cardioplegia

2058 ± 236

2323 ± 365

urine (ml) during CPB

822 ± 483

838 ± 378

total urine production (ml)

1455 ± 532

1538 ± 546

use of filter, n (%)

11 (11.0%)

20 (21.7%)##

Overall fluid balance

390 ± 432

667 ± 553

Calculated erythrocyte volume loss

758 ± 299

903 ± 303##

# p < 0.05

## p < 0.005

p < 0.001

p < 0.0001

There were no OR deaths in either group. Mechanical ventilation duration ranged from 5 to 52 hours (mean = 9.5, median = 9) in group A, and from 5 to 70 hours (mean = 13.2, median = 10) in group B. ICU LOS ranged from 1 to 10 days (mean = 2.6, median = 2) in group A, and from 1 to 8 days (mean = 3.2, median = 2) in group B. Mechanical ventilation duration and ICU LOS did not differ significantly between groups. Likewise, postoperative LOS in the ward did not differ between groups (8.4 ± 2.2 in group A vs. 8.1 ± 2.9 in group B). ICU complications included MI (5 pt), persistent significant arrhythmia (third-degree atrioventricular heart block, supraventricular tachyarrhythmias or symptomatic ventricular arrhythmias) (8 pts), low output syndrome delaying extubation (6 pts) and persistent neurological dysfunction (1 pt) in group A and MI (4 pt), arrhythmia (6 pts), low output syndrome (7 pt), and lower extremity ischemia (1 pt) in group B. Excluding patients with complications in the ICU, ventilation time >24 h occurred in 5 group A patients and 6 group B patients. Reoperation for bleeding occurred in one group A patient who had not been transfused during the initial operation, and one group B patient who had already been transfused during the initial operation. In total, re-explored patients received 4 and 6 PRC units respectively. One patient in each group developed renal failure and required dialysis. Finally, among patients with complications, two group A patients (one had CABG, one had AVR) and one group B patient (had CABG) died in the 30-day postoperative period.

Discussion

Decisions regarding PRC transfusion are based on a multimodal approach in cardiac surgery, and the correct, if any, transfusion trigger remains contentious. We designed this study because we believe that fluid balance is a modifiable variable that can impact hematocrit and thereby influence the number of PRC units transfused. The study demonstrated reduced intraoperative PRC transfusion and less positive fluid balance in the "restricted fluid" group, while hematocrit values were not significantly different between groups at the end of the operation. Among patients who received intraoperative PRC transfusions, significantly fewer belonged to group A. Postoperatively, the number of transfused patients and the number of PRC units did not differ significantly between groups.

We propose that the lower transfusion rate in group A is attributable to our protocol, which was designed to avoid unnecessary fluid loading. Hematocrit and fluid balance differed significantly between groups after CPB and at the end of surgery, because group A patients received fluids only for hypovolemia, but not to compensate for vasodilatation or poor cardiac performance. Our study showed that relatively small differences in parenteral fluid administration can significantly influence intraoperative transfusion.

Strengths of this study include study design (prospective, randomized, adequate power). Use of a well-defined PRC transfusion protocol and having all operations performed by the same team under similar conditions makes the study stronger, and the low number of deaths resulted in data with few missing data points.

Study limitations include certain aspects of study design (no formal blinding, different anesthesiologists in different cases). Furthermore, our low mortality may reduce generalizability of the results, as our conclusions may not be applicable in cardiac surgery centers where more transfusions are needed because of higher surgical complication rates. In addition, lack of standardization with regards to intravenous fluid administration in group B (liberal fluids) is also a limitation. We believe that the observed difference between groups concerning replacement solutions probably resulted from use of a carrier fluid and from "liberal" fluid administration in group B. Unfortunately, this important difference between groups only became obvious during data analysis. However, we believe this important limitation is not necessarily a major drawback because, as group B patients received approximately 50% crystalloid and 50% colloid, both groups overall received similar amounts of colloid, and only differed in the amount of crystalloids given to group B.

Despite receiving more PRC units during CPB, group B patients had lower intraoperative Hct values (Table 8). In addition to hemodilution from liberal fluid administration, the observed differences between groups could also be attributed to variability in the transfusion trigger and variability in fluid administration during CPB between groups: The study protocol required that Clinicians in Group A consider more sophisticated data like INVOS values before initiating a blood transfusion, whereas group B patients were transfused at the discretion of the attending anaesthesiologist when Hct values were between 17-21%. Absence of a protocol for transfusion of other blood products (FFP, platelets, and cryoprecipitate) should also be pointed out as a weakness, because differences in treatment of coagulation abnormalities could result in greater variability of blood loss, and possibly of transfusions.

As advanced age, female gender, low BSA and preoperative anemia have been identified as independent predictors of PRC transfusion in cardiac surgery [5, 7, 8, 11], blood loss and CPB initiation are expected to have a greater impact on hemoglobin concentration in these patient categories. Patients who received transfusions in our study differed significantly, compared to patients who were not transfused with regards to these variables. Logistic regression showed that fluid restriction is a significant factor, decreasing the probability of transfusion to 0.32. Likewise, low preoperative hematocrit was also identified as significant: the probability of transfusion in a patient with 36% preoperative hematocrit is almost twice the probability of a patient with preoperative hematocrit of 42%. Mean preoperative hematocrit was significantly lower in transfused patients compared to those not transfused (Table 2). In addition, among patients transfused in the OR, hematocrit in group A did not differ significantly compared to group B (Table 4). Consequently, preoperative anemia seems to predispose to transfusion even under a fluid restriction protocol. Subgroup analysis of our data could perhaps help us extract clear conclusions regarding specific population groups (e.g. low BMI patients). However, because our study did not have adequate power for subgroup analysis, appropriately designed rigorous clinical trials are needed to fully determine the effect of intra-operative fluid restriction in specific population groups.

Wide variations in reported transfusion practices [10, 12] probably reflect variability between institutions, but also indicate that transfusion decisions have a degree of subjectivity [7, 12]. It seems that we, as anesthesiologists, do not really know the degree of hemodilution that can be tolerated by each patient. A significant proportion of intraoperative transfusions occur during CPB, when SVO2 monitoring is impossible, and blood samples drawn from the venous cannula give an inconclusive picture about tissue oxygenation, because the heart is bypassed and hemoglobin saturation values are normalized by cold, less oxygen-consuming tissues. In our study, transfusion decisions during CPB were based on hematocrit value, clinical condition, INVOS data, time to release aortic clamp, temperature and urine production. We believe that two factors influenced transfusion decisions during this period: experience of the anesthesiologist (interpretation of the above parameters) and protocol. Less experienced anesthesiologists may have responded to excessive hemodilution (more likely in group B) with unnecessary transfusions. The strict INVOS-based protocol and the directions for using BIS data in group A may have also played a role, but the true value of INVOS with regards to transfusion decisions in cardiac surgery is unknown. For example, we do not know how to treat a patient with hematocrit less than 17% with normal INVOS values during CPB. Is transfusion justified at this point? Existing reports raise concerns regarding safety when proceeding with low hematocrit values [13, 14]. In any case, low hematocrit values during CPB are associated with excessive hemodilution. Finally, BIS data may have prompted the anesthesiologist to intervene directly or indirectly to aspects of patient care other than hypnotic state depth [15].

The observed difference of calculated erythrocyte volume loss between the two groups deserves comment, because blood loss affects transfusion decisions. First, this difference is difficult to explain, because the two groups originated from randomization, had similar baseline data, were operated under exactly the same conditions, and surgery duration did not differ significantly between groups. Second, erythrocyte volume loss calculations are based on formulas taking into account preoperative patient data. Consequently, because allogeneic red cells can be displaced from the circulation earlier than native erythrocytes, erythrocyte volume loss can be overestimated as the number of transfused units increases. In any case, we certainly have some reservation regarding the validity of these methods.

Outcome data, other than PRC transfusions, did not differ significantly between groups in our study. However, this study was designed to compare PRC transfusions between groups, and did not have the power to show differences with regards to other important outcomes, such as renal failure, length of stay, morbidity or mortality. Because such comparisons are beyond the size and scope of our study, we believe that convincing answers to these important questions can only come from well designed future studies with much larger patient populations.

Conclusions

The results of this study show that intraoperative IV fluid restriction combined with red cell salvage and a well-defined PRC transfusion protocol reduces intraoperative PRC transfusion in cardiac surgery without significantly increasing postoperative PRC transfusion. The benefits of fluid restriction are more pronounced in patients prone to transfusion (such as aged females, patients with low BSA or low preoperative hematocrit). Current evidence suggests that physician transfusion practices can be improved. Consequently, appropriately designed rigorous clinical trials are needed to confirm the validity of our findings and determine the combined effectiveness of new monitoring modalities and intraoperative fluid restriction on blood conservation, and their role on rational decision-making regarding PRC transfusion in cardiac surgery.

List of Abbreviations

ACT: 

activated clotting time

AOX: 

aortic cross-clamping

ASD: 

atrial septal defect

AVR: 

aortic valve replacement

BIS: 

bispectral index

BMI: 

body mass index

BSA: 

body surface area

CABG: 

coronary artery bypass grafting

CI: 

confidence interval

COPD: 

chronic obstructive pulmonary disease

CPB: 

cardio-pulmonary by pass

ECG: 

electrocardiogram

Hct: 

hematocrit

ICU: 

Intensive Care Unit

INVOS: 

near infrared spectroscopy

IV: 

intravenous

LOS: 

length of stay

LVEF: 

left ventricular ejection fraction

MI: 

myocardial infarction

MAP: 

mean arterial pressure

MVR: 

mitral valve replacement

NYHA: 

New York Heart Association

OR: 

Operating Room

PCWP: 

pulmonary capillary wedge pressure

PRC: 

packed red cells

RCT: 

randomized control trial

SD: 

standard deviation

SvO2

mixed venous oxygen saturation.

Declarations

Acknowledgements

The authors are indebted to several people for their contribution to this work. We thank the anesthesiologists V. Tasoudis, K. Kyriakaki and J. Moutos for their participation and the statistician G. Dimakopoulos for statistical analysis. We also thank the cardiac surgeon N. Tsilimingas, the assistants A. Hevas and G. Kalafati, our chief perfusionist V. Mitilis and the nursing personnel of the University Hospital of Larissa who worked willingly in the OR and ICU for the collection of the data.

Authors’ Affiliations

(1)
Cardiac Anesthesia Unit, Department of Anesthesiology, University Hospital of Larissa
(2)
Department of Anaesthesiology and Critical Care, University of Patras School of Medicine
(3)
Department of Vascular Surgery, University Hospital of Larissa

References

  1. Scott BH, Seifert FC, Grimson R: Blood transfusion is associated with increased resource utilisation, morbidity and mortality in cardiac surgery. Ann Card Anaesth. 2008, 11: 15-19. 10.4103/0971-9784.38444.View ArticlePubMedGoogle Scholar
  2. Oliver E, Carrio ML, Rodriguez-Castro D, Javierre C, Farrero E, Torrado H, Castells E, Ventura JL: Relationships among haemoglobin level, packed red cell transfusion and clinical outcomes in patients after cardiac surgery. Intensive Care Med. 2009, 35: 1548-1555. 10.1007/s00134-009-1526-0.View ArticlePubMedGoogle Scholar
  3. Weightman WM, Gibbs NM, Sheminant MR, Newman MA, Grey DE: Moderate exposure to allogeneic blood products is not associated with reduced long-term survival after surgery for coronary artery disease. Anesthesiology. 2009, 111: 327-333. 10.1097/ALN.0b013e3181ab6743.View ArticlePubMedGoogle Scholar
  4. Whitson BA, Huddleston SJ, Savik K, Shumway SJ: Risk of Adverse Outcomes Associated With Blood Transfusion After Cardiac Surgery Depends on the Amount of Transfusion. J Surg Res. 2010, 158: 20-7. 10.1016/j.jss.2008.10.015.View ArticlePubMedGoogle Scholar
  5. Arora RC, Legare JF, Buth KJ, Sullivan JA, Hirsch GM: Identifying patients at risk of intraoperative and postoperative transfusion in isolated CABG: toward selective conservation strategies. Ann Thorac Surg. 2004, 78: 1547-1554. 10.1016/j.athoracsur.2004.04.083.View ArticlePubMedGoogle Scholar
  6. Dial S, Delabays E, Albert M, Gonzalez A, Camarda J, Law A, Menzies D: Hemodilution and surgical hemostasis contribute significantly to transfusion requirements in patients undergoing coronary artery bypass. J Thorac Cardiovasc Surg. 2005, 130: 654-661. 10.1016/j.jtcvs.2005.02.025.View ArticlePubMedGoogle Scholar
  7. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, Saha SP, Hessel EA, Haan CK, Royston BD, Bridges CR, Higgins RS, Despotis G, Brown JR, Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion, Spiess BD, Shore-Lesserson L, Stafford-Smith M, Mazer CD, Bennett-Guerrero E, Hill SE, Body S: Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007, 83: S27-S86. 10.1016/j.athoracsur.2007.02.099.View ArticleGoogle Scholar
  8. Karkouti K, Cohen MM, McCluskey SA, Sher GD: A multivariable model for predicting the need for blood transfusion in patients undergoing first-time elective coronary bypass graft surgery. Transfusion. 2001, 41: 1193-1203. 10.1046/j.1537-2995.2001.41101193.x.View ArticlePubMedGoogle Scholar
  9. Vretzakis G, Kleitsaki A, Stamoulis K, Dragoumanis Ch, Tasoudis V, Kyriakaki K, Microulis D, Giannoukas A, Tsilimingas N: The impact of fluid restriction policy in reducing the use of red blood cells in cardiac surgery. Acta Anaesth Belg.Google Scholar
  10. Rogers MA, Blumberg N, Saint S, Langa KM, Nallamothu BK: Hospital variation in transfusion and infection after cardiac surgery: a cohort study. BMC Med. 2009, 7: 37-10.1186/1741-7015-7-37.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology. 2006, 105: 198-208. 10.1097/00000542-200607000-00030.Google Scholar
  12. Stover EP, Siegel LC, Parks R, Levin J, Body SC, Maddi R, D'Ambra MN, Mangano DT, Spiess BD: Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines: a 24-institution study. Institutions of the Multicenter Study of Perioperative Ischemia Research Group. Anesthesiology. 1998, 88: 327-333. 10.1097/00000542-199802000-00009.View ArticlePubMedGoogle Scholar
  13. Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ, Shah A: Adverse effects of low hematocrit during cardiopulmonary bypass in the adult: should current practice be changed?. J Thorac Cardiovasc Surg. 2003, 125: 1438-1450. 10.1016/S0022-5223(02)73291-1.View ArticlePubMedGoogle Scholar
  14. Karkouti K, Djaiani G, Borger MA, Beattie WS, Fedorko L, Wijeysundera D, Ivanov J, Karski J: Low hematocrit during cardiopulmonary bypass is associated with increased risk of perioperative stroke in cardiac surgery. Ann Thorac Surg. 2005, 80: 1381-1387. 10.1016/j.athoracsur.2005.03.137.View ArticlePubMedGoogle Scholar
  15. Vretzakis G, Ferdi E, Argiriadou H, Papaziogas B, Mikroulis D, Lazarides M, Bitzikas G, Bougioukas G: Influence of bispectral index monitoring on decision making during cardiac anesthesia. J Clin Anesth. 2005, 17: 509-516. 10.1016/j.jclinane.2004.12.018.View ArticlePubMedGoogle Scholar

Copyright

© Vretzakis et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement